2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
76
Neoplasms
29
Thyroid Neoplasms
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
10
Thyroid Carcinoma, Anaplastic
9
Glioma
9
Brain Neoplasms
9
Multiple Myeloma
7
Colorectal Neoplasms
7
Skin Neoplasms
6
Hematologic Neoplasms
6
Thyroid Cancer, Papillary
4
Ameloblastoma
4
Lung Neoplasms
3
Histiocytosis, Langerhans-Cell
3
Glioblastoma
3
Astrocytoma
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Ganglioneuroma
2
Interventions
Vancomycin
4
pegfilgrastim
3
Cefepime
3
trametinib
2
liposomal amphotericin B
2
dabrafenib
2
Piperacillin, Tazobactam Drug Combination
2
Meropenem
2
Filgrastim
2
Ciprofloxacin
2
Ceftazidime
2
Caspofungin
2
ofatumumab
1
ceftobiprole medocaril
1
Teicoplanin
1
Tazobactam
1
Surveys and Questionnaires
1
Ritonavir
1
Quality of Life
1
Povidone-Iodine
1
Piperacillin
1
Moxifloxacin
1
Metformin
1
Mannose-Binding Lectin
1
Levofloxacin
1
Lenalidomide
1
Itraconazole
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fever
×
dabrafenib
×
Clear all
NCT01972347
2025-12-16
Neo Combi
Melanoma Institute Australia
Phase 2
Active not recruiting
35 enrolled
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts